Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

November is historically Wall Street's strongest month. These 7 stocks often delivered standout gains in recent decades.

In this week’s edition of InnovationRx, we look at the Nobel Prize winners in medicine, Amgen’s direct-to-consumer effort, ...

A separate debate NBC 6 held this month featured four candidates — González, Higgins, Russell and Suarez — who polled above ...

The KOSPI surged by 19.94% in October, marking the highest monthly return since November 2001 (19.72%). Above all ... On the 3rd, Palantir will release its results, followed by AMD, Uber, and Pfizer ...

Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. The 6.7% ...

Pfizer Inc. has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Despite skepticism over Pfizer's recent acquisitions, Metsera's ...

This is read by an automated voice. Please report any issues or inconsistencies here. President Trump’s deal with Pfizer on drug prices won’t do much for American patients, but it’s great for Pfizer.

Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. Pfizer is ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...